Lv21
110 积分 2023-07-10 加入
Is Delayed Image of 18F-FDG PET/CT Necessary for Mediastinal Lymph Node Staging in Non–Small Cell Lung Cancer Patients?
1个月前
已完结
Clinical Features and Management of Congenital Fibrinogen Deficiencies
1个月前
已完结
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
3个月前
已完结
Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference
3个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
4个月前
已关闭
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
4个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
7个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
7个月前
已完结
Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
8个月前
已完结
Utility of Pre-clinical Dosimetry Evaluation in Estimating Human Absorbed Doses for First-in-Human Studies with 11C- and 18F-labeled Radiopharmaceuticals: an FDA Perspective
9个月前
已关闭
皖公网安备34019202002308
